Pfizer Inc. PFE today announced that the European Commission has
approved a label update to expand use of XALKORI® (crizotinib) to
first-line treatment of adults with anaplastic lymphoma kinase
(ALK)-positive advanced non-small cell lung cancer (NSCLC). The Summary
of Product Characteristics also has been updated to include efficacy
data from PROFILE 1014, which demonstrated that XALKORI significantly
prolonged progression-free survival (PFS) in previously untreated
patients with ALK-positive advanced nonsquamous NSCLC when compared to
standard platinum-based chemotherapy regimens.1
"The European Commission's decision to approve XALKORI in the first-line
setting reinforces XALKORI's role as a standard of care for patients
with ALK-positive advanced NSCLC," said Andreas Penk, MD, regional
president
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in